<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Pharmacother</journal-id><journal-id journal-id-type="iso-abbrev">Ann Pharmacother</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The Annals of pharmacotherapy</journal-title></journal-title-group><issn pub-type="ppub">1060-0280</issn><issn pub-type="epub">1542-6270</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10508332</article-id><article-id pub-id-type="pmcid-ver">PMC10508332.1</article-id><article-id pub-id-type="pmcaid">10508332</article-id><article-id pub-id-type="pmcaiid">10508332</article-id><article-id pub-id-type="manuscript-id">NIHMS1924453</article-id><article-id pub-id-type="pmid">35942598</article-id><article-id pub-id-type="doi">10.1177/10600280221113299</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1924453</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1924453</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Co-prescribing of Central Nervous System-Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sood</surname><given-names initials="A">Akhil</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuo</surname><given-names initials="YF">Yong-Fang</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Westra</surname><given-names initials="J">Jordan</given-names></name><degrees>MPH</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharma</surname><given-names initials="G">Gulshan</given-names></name><degrees>MD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raji</surname><given-names initials="MA">Mukaila A.</given-names></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555-01777</aff><aff id="A2"><label>2</label>Department of Preventive Medicine &amp; Population Health, University of Texas Medical Branch, Galveston, TX, 77555-01777</aff><aff id="A3"><label>3</label>Department of Pulmonary, Critical Care, &amp; Sleep Medicine, University of Texas Medical Branch, Galveston, TX, 77555-01777</aff><aff id="A4"><label>4</label>Department of Geriatric Medicine, University of Texas Medical Branch, Galveston, TX, 77555-01777</aff><author-notes><corresp id="CR1"><underline>Corresponding Author</underline>: Akhil Sood, MD, Department of Internal Medicine, University of Texas Medical Branch (UTMB), 301 University Blvd, Galveston, TX 77555-0177., Phone: (409) 772-1987, Fax: (409) 747-3585, <email>aksood@utmb.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P41">Conflict of Interest: The authors report no conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>8</month><year>2022</year></pub-date><volume>57</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">445527</issue-id><fpage>382</fpage><lpage>396</lpage><pub-history><event event-type="nihms-submitted"><date><day>31</day><month>08</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 14:25:13.177"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1924453.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P1">Anxiety and chronic pain are common comorbidities in patients with Chronic Obstructive Pulmonary Disease (COPD), which are frequently managed with benzodiazepines (BZD) and opioids, respectively.</p></sec><sec id="S2"><title>Objective</title><p id="P2">The purpose of this study was to determine if different combinations of opioids, benzodiazepines, and their substitutes &#8211; gabapentinoids (GABA) and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRI/SNRI)&#8211; are associated with lower risk of acute respiratory events in COPD patients with co-occurring chronic pain and anxiety.</p></sec><sec id="S3"><title>Methods</title><p id="P3">This retrospective cohort study used a nationally representative sample of Medicare beneficiaries with COPD, chronic pain, and anxiety. Patients were grouped based on drug combination (opioid + BZD/Z-hypnotics, opioid + GABA, opioid + SSRI/SNRI, BZD/Z-hypnotics + GABA, BZD/Z-hypnotics + SSRI/SNRI, GABA + SSRI/SNRI, or &#8805;3 drugs). The primary outcome was emergency room (ER) visit or hospitalization due to acute respiratory events assessed up to 180 days following initiation of drug combination. Overdose secondary to central nervous system (CNS)-related drugs was also assessed up to 180 days following initiation of drug combination.</p></sec><sec id="S4"><title>Results</title><p id="P4">The drug combination opioid + GABA was associated with decreased risk for ER visit (HR 0.73 95% CI 0.61&#8211;0.87) and hospitalization (HR 0.69 95% CI 0.55&#8211;0.85). Opioid + SSRI/SNRI also showed decreased risk for ER visit (HR 0.84 95% CI 0.71&#8211;0.99). There was no significant difference in risk for CNS-related drug overdose among different drug combinations compared to opioid + BZD/Z-hypnotics.</p></sec><sec id="S5"><title>Conclusion and Relevance</title><p id="P5">Opioids in combinations with GABA and SSRI/SNRI demonstrate relatively lower risk for acute respiratory events among patients with COPD and comorbid chronic pain and anxiety. The findings emphasize the need for multimodal management in this vulnerable population.</p></sec></abstract><kwd-group><kwd>COPD</kwd><kwd>Opioids</kwd><kwd>Benzodiazepines</kwd><kwd>Gabapentinoids</kwd><kwd>Selective Serotonin Reuptake Inhibitors</kwd><kwd>Serotonin and Norepinephrine Reuptake Inhibitors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>